186185-03-5 Usage
Uses
1. Used in Pharmaceutical Applications:
1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3,5-dimethyl ester L-Lactate is used as a pharmaceutical compound for its potential therapeutic effects. Its specific molecular structure may allow it to interact with various biological targets, such as receptors or enzymes, which could be beneficial in the treatment of certain medical conditions.
2. Used in Chemical Research:
1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate can also be utilized in chemical research as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique structure and functional groups may provide valuable insights into the development of new chemical entities with specific applications in various fields.
3. Used in Drug Delivery Systems:
Similar to gallotannin, 1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3,5-dimethyl ester L-Lactate may be employed in the development of novel drug delivery systems. Its chemical properties could be harnessed to improve the delivery, bioavailability, and therapeutic outcomes of various drugs, particularly in the context of cancer treatment.
4. Used in the Development of Neuropeptide Y1 Antagonists:
Given its structural complexity and potential for interaction with biological targets, 1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate may be used in the development of neuropeptide Y1 (NPY Y1) antagonists. These antagonists, such as BMS 193885, have been shown to reduce food intake and body weight through central Y1 inhibition, making them potential candidates for the treatment of obesity and related metabolic disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 186185-03-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,6,1,8 and 5 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 186185-03:
(8*1)+(7*8)+(6*6)+(5*1)+(4*8)+(3*5)+(2*0)+(1*3)=155
155 % 10 = 5
So 186185-03-5 is a valid CAS Registry Number.
186185-03-5Relevant articles and documents
Dihydropyridine neuropeptide Y Y1 receptor antagonists 2: Bioisosteric urea replacements
Poindexter, Graham S.,Bruce, Marc A.,Breitenbucher, J. Guy,Higgins, Mendi A.,Sit,Romine, Jeffrey L.,Martin, Scott W.,Ward, Sally A.,McGovern, Rachel T.,Clarke, Wendy,Russell, John,Antal-Zimanyi, Ildiko
, p. 507 - 521 (2007/10/03)
Structure-activity studies around the urea linkage in BMS-193885 (4a) identified the cyanoguanidine moiety as an effective urea replacement in a series of dihydropyridine NPY Y1 receptor antagonists. In comparison to urea 4a (Ki=3.3
Dihydropyridine neuropeptide Y Y1 receptor antagonists
Poindexter, Graham S.,Bruce, Marc A.,LeBoulluec, Karen L.,Monkovic, Ivo,Martin, Scott W.,Parker, Eric M.,Iben, Larry G.,McGovern, Rachel T.,Ortiz, Astrid A.,Stanley, Jennifer A.,Mattson, Gail K.,Kozlowski, Michael,Arcuri, Meredith,Antal-Zimanyi, Ildiko
, p. 379 - 382 (2007/10/03)
Dihydropyridine 5a was found to be an inhibitor of neuropeptide Y1 binding in a high throughput 125I-PYY screening assay. Structure-activity studies around certain portions of the dihydropyridine chemotype identified BMS-193885 (6e)
